Hospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (113)

2024

  1. Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients

    Cytokine, Vol. 177

  2. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas

    International Journal of Gynecological Cancer, Vol. 34, Núm. 10, pp. 1499-1521

2023

  1. European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors

    International Journal of Gynecological Cancer, Vol. 33, Núm. 10, pp. 1621-1626

2022

  1. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

    Gynecologic Oncology, Vol. 165, Núm. 1, pp. 40-48

2021

  1. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer

    Oncologist, Vol. 26, Núm. 4, pp. e658-e668

  2. Complete Spontaneous Regression of Lung Metastases after Resection of CIC-Rearranged Sarcoma: A Case Report

    Case Reports in Oncology, Vol. 14, Núm. 1, pp. 152-159

  3. Cáncer ginecológico en la anciana

    Revisiones en Cancer, Vol. 35, Núm. 5, pp. 209-217

  4. Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients? a study protocol

    Cancers, Vol. 13, Núm. 1, pp. 1-14

  5. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report

    World Journal of Surgical Oncology, Vol. 19, Núm. 1

  6. SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 922-930

2020

  1. Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

    Angiogenesis, Vol. 23, Núm. 4, pp. 543-557

  2. Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

    Frontiers in Oncology, Vol. 9

2019

  1. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

    Obstetrical and Gynecological Survey

  2. Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer

    Future Oncology, Vol. 15, Núm. 3, pp. 271-280

2018

  1. Expression III: Patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

    Annals of Oncology, Vol. 29, Núm. 4, pp. 910-916

  2. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

    The Lancet Oncology, Vol. 19, Núm. 12, pp. 1680-1687

  3. Nuevas dianas terapéuticas y líneas de investigación en los sarcomas de partes blandas

    Revisiones en Cancer, Vol. 32, Núm. 3, pp. 153-165

  4. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study

    Investigational New Drugs, Vol. 36, Núm. 3, pp. 468-475

  5. SEOM clinical guideline on unknown primary cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 89-96

  6. SEOM clinical guidelines in gestational trophoblastic disease (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 38-46